Effects of Artemisia argyi on Nonalcoholic Steatohepatitis and Changes in the Gut Microbiota

Erdenebileg, SaruulKim, Myung SukNam, YunseongNho, Chu Won
Issue Date
The Korean Society of Food Science and Nutrition (KFN)
2022년도 한국식품영양과학회 국제심포지엄, 정기학술대회 및 정기총회 (2022 KFN International Symposium and Annual Meeting, New Frontiers for Green Biotechnology in Food Science and Nutrition)
Nonalcoholic steatohepatitis is one of the leading causes of fibrosis. Artemisia argyi (AA) has been a traditional medicine for alleviating pain in the lower abdomen, and inflammation. To determine the therapeutic effect of AA ethanol extract and its active compounds, we induced the fibrosis using TGF-β-treated human hepatic stellate LX-2 cells and a choline-deficient L-amino acid-defined high-fat diet (CDAHFD)-induced NASH model. Eupatilin, Chlorogenic acid, and Jaceosidin known to be isolated from AA ethanol extract significantly reduced the expression of fibrosis-related markers in LX-2 cells. In addition, oral administration of AA ethanol extract inhibited the production of liver injury markers, lipid profiling and mRNA expression of fibrosis-related markers. As a result of 16S rRNA sequencing analysis to determine whether the anti-fibrosis effect is mediated by intestinal microbes, the abundance of Acetivibrio ethanolgignens was significantly reduced by AA compared to the CDAHFD group and showed a significant correlation with fibrosis-related markers. These results suggest that AA is a promising therapeutic candidate for fibrosis and liver disease in CDAHFD-induced mice.
Appears in Collections:
KIST Conference Paper > 2022
Files in This Item:
There are no files associated with this item.
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.